TULIP-SC trial – Talk Bio

Actionable Insights Powered by AI

AstraZeneca’s Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment

14 hours ago talkbio0Tagged anifrolumab, AstraZeneca, Clinical Trials, disease activity, Encephalitis, St. Louis, Lupus Erythematosus, Systemic, Phase III, Saphnelo, Self-Injectable, subcutaneous, TULIP-SC trial

AstraZeneca; Saphnelo; anifrolumab; Phase III; TULIP-SC trial; systemic lupus erythematosus; SLE; self-injectable; subcutaneous; clinical trial; disease activity reduction